If we trace the revenue from the manufacturer down to the patient, we see a stark contrast between the current global monopoly model and the impending Indian generic reality
Like most health insurers, Blue Cross covers medications when medically necessary for patients with type 2 diabetes, including GLP-1s, but does not cover requests for off-label use
Noom, best-known for its weight loss app and more recent GLP-1 offering, launched an HRT program for menopause in late February, and telehealth company Hims & Hers plans to roll out at-home testing over the next year to enable care for low testosterone, perimenopause, and menopause
This hormonal imbalance is driven by two mechanisms problems with the brains hypothalamus and insulin resistance
Suppliers that emphasize purity testing, transparency, and product consistency stand out in an increasingly competitive market
The lack of safety data is itself a risk